Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2014, Article ID 516593, 7 pages
http://dx.doi.org/10.1155/2014/516593
Research Article

Anti-hnRNP B1 (RA33) Autoantibodies Are Associated with the Clinical Phenotype in Russian Patients with Rheumatoid Arthritis and Systemic Sclerosis

1Department of Rheumatology, Almazov Medical Research Centre, 197341 St. Petersburg, Russia
2Laboratory of Autoimmune Diagnostics, St. Petersburg Pavlov State Medical University, 197022 St. Petersburg, Russia
3Eichwald Department of Therapy and Rheumatology, Mechnikov Northwestern State University, 191015 St. Petersburg, Russia
4Faculty of Science, Brandenburg University of Technology Cottbus-Senftenberg, Großenhainer Straße 57, 01968 Senftenberg, Germany
5R/D, Medipan GmbH, Dahlewitz, 15827 Berlin, Germany
6Institute of Liver Studies, Division of Transplantation Immunology and Mucosal Biology, King’s College London School of Medicine at King’s College Hospital, London SES 9RJ, UK

Received 14 January 2014; Revised 9 April 2014; Accepted 9 April 2014; Published 4 May 2014

Academic Editor: Michael Mahler

Copyright © 2014 Aleksey Maslyanskiy et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Supplementary Material

Comparison of the novel anti-hnRNP B1 enzyme-linked immunosorbent assay (ELISA) with a commercially available ELISA detecting anti-hnRNP A2 (RA33) antibodies and an immunoblot assay analyzing anti-hnRNP B1 antibodies

For the correlation of anti-hnRNP B1 antibody analysis by the novel ELISA with anti-hnRNP A2 (RA33) antibody detection by a commercially available ELISA (HUMAN, Wiesbaden, Germany), 299 sera of patients suffering from rheumatoid arthritis (RA) were tested by both methods (Supplementary Figure 1). There was a weak, yet significant, correlation between both anti-hnRNP antibody assays (Spearman’s rho = 0.209, 95% confidential interval: 0.098 – 0.315; 𝑃 < 0.001).

To confirm the specificity of anti-hnRNP B1 antibody detection by the novel ELISA, 10 sera of 5 patients suffering from RA and 5 patients with systemic sclerosis (SSc) each demonstrating anti-hnRNP B1 IgG positivity were tested by immunoblot assay employing the recombinant hnRNP B1 polypeptide. All 10 sera demonstrated a clear positive reaction of IgG to the hnRNP B1 polypeptide blotted onto a nitrocellulose membrane (Supplementary Figure 2).

  1. Supplementary Material